Inactivating mutations in NPC1L1 and protection from coronary heart disease.

BACKGROUND: Ezetimibe lowers plasma levels of low-density lipoprotein (LDL) cholesterol by inhibiting the activity of the Niemann-Pick C1-like 1 (NPC1L1) protein. However, whether such inhibition reduces the risk of coronary heart disease is not known. Human mutations that inactivate a gene encoding...

Full description

Bibliographic Details
Main Authors:	Stitziel, N, Won, H, Morrison, A, Peloso, G, Do, R, Lange, L, Fontanillas, P, Gupta, N, Duga, S, Goel, A, Farrall, M, Saleheen, D, Ferrario, P, König, I, Asselta, R, Merlini, P, Marziliano, N, Notarangelo, M, Schick, U, Auer, P, Assimes, T, Reilly, M, Wilensky, R, Rader, D, Hovingh, G
Format:	Journal article
Language:	English
Published:	Massachussetts Medical Society 2014

Inactivating mutations in NPC1L1 and protection from coronary heart disease.

Similar Items